# Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids

> **NCT02465814** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 120 (actual)

## Conditions studied

- Leiomyoma

## Interventions

- **DRUG:** Vilaprisan (BAY1002670)
- **DRUG:** Vilaprisan (BAY1002670
- **DRUG:** Vilaprisan (BAY1002670
- **DRUG:** Vilaprisan (BAY1002670)
- **DRUG:** Ulipristal
- **DRUG:** Ulipristal
- **DRUG:** Ulipristal

## Key facts

- **NCT ID:** NCT02465814
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2016-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02465814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02465814, "Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02465814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*